Searched for
DIABETES DRUGS
Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDAEli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (U...- Pharma industry steps up API investments to cut import dependence, move up value chainIndia's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Invest...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analystsGlobal markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at ...
- Dr Reddy's Laboratories receives ANVISA approval for generic semaglutide injection in BrazilDr Reddy’s Laboratories obtained marketing authorisation from Brazil’s ANVISA for a generic semaglutide injection. The product will be avai...
- Sun Pharma’s specialty portfolio, Organon deal to drive growthSun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines....
- India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugsOver the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth ...
- Drug-free treatment for diabetes and obesity may become possible as scientists develop a wireless device that detects high blood sugar levels and removes excess sugar from bloodstreamDiabetes treatment news: A team of scientists from France and Switzerland developed a wireless electronic device to manage diabetes. This d...
- Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhen a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling u...
- Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...
- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Silver dividends: How investing in ageing societies can boost growth and cut healthcare costsAs populations age and people work longer, governments can turn longevity into an economic opportunity by investing in accessible infrastru...
- VIP culture in hospitals can compromise patient safety, equitable care: AIIMS doctorsAIIMS Delhi doctors discuss the ethical challenges posed by preferential treatment for VIP patients in healthcare. They emphasize that such...
- DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruptionDr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...
- Beauty firms chase 'Ozempic face' market as weight-loss drugs boomGalderma, Natura, and L'Oreal are developing treatments for consumers experiencing facial sagging due to rapid weight loss. These companies...
- As weight-loss drug users turn to dietary supplements, doctors, regulators raise flagsThe growing use of GLP-1 weight-loss drugs such as Ozempic and Wegovy is driving demand for dietary supplements in the US, as users seek to...
- GLP-1 and fertility: Could weight-loss medicines help women conceive? Here's what new reports revealinsulin resistance can disrupt reproductive hormones. For women with polycystic ovary syndrome (PCOS), ovulation may become irregular. Gett...
Load More
